On January 9, 2025, the National Healthcare Security Administration held a symposium to support the development of innovative drugs, exchanging information with some pharmaceutical companies on the development of innovative drugs and listening to opinions and suggestions on the medical insurance department's support for the development of innovative drugs. BeiGene, Beida Pharmaceutical, Jiangsu Hengrui, CR Sanjiu, Roche, Johnson&Johnson, Sanofi, Astellas and other companies participated in the symposium, introduced relevant situations and put forward opinions and suggestions.

The meeting pointed out that the National Healthcare Security Administration resolutely implements the decision-making and deployment of the Party Central Committee and the State Council. While insisting on managing the medication medical insurance fund well and striving to relieve the worries of all people about medical treatment for diseases, it continuously improves the medical insurance system, optimizes medical insurance management services, plays a strategic purchasing role, provides stable and sustained sources of funding for the innovative development of the pharmaceutical industry, and strongly supports the high-quality development of the innovative pharmaceutical industry.

To further increase support for innovative drugs, the National Healthcare Security Administration will research and introduce a series of more powerful policy measures based on thorough research and extensive solicitation of opinions.

It mainly includes the following six aspects;

1. We will focus on improving the "1+3+N" multi-level security system and expanding payment channels for innovative drugs;

2. Explore the establishment of a Class C drug catalog and guide the inclusion of innovative drugs in the coverage responsibility of welfare oriented commercial health insurance;

3. Optimize the management of initial release prices for innovative drugs and the online procurement process to improve online efficiency;

4. Continuously and dynamically adjust the list of medical insurance drugs, timely include innovative drugs that meet the conditions, and stabilize enterprise expectations;

5. Promote designated medical institutions and retail pharmacies to equip drugs and encourage the clinical application of innovative drugs;

6. Utilize the rich experience of the centralized drug procurement platform, actively strengthen external publicity, and support the pharmaceutical industry to "go global" and seek broader markets.